Ip, MD, discusses the available treatments for nonproliferative diabetic retinopathy. Ip said about 50% of responders to an American Society of Retina Specialists survey reported that they were ...

HealthDay News — Empagliflozin initiation is not associated with incident nonproliferative diabetic retinopathy (NPDR) compared with initiation of a dipeptidyl peptidase 4 inhibitor (DPP4i), according ...

The collaboration will focus on preventive solutions, workshops, and public awareness. King Faisal Specialist Hospital and ...

Diabetic retinopathy is a serious concern for people dealing with diabetes. Detecting diabetic retinopathy poses significant challenges, requiring skilled professionals, extensive manual image ...

Arogya Aarohan app & other AI-driven tools are being tested for early detection of diseases as part of Rs 300-cr initiative ...

Diabetic retinopathy (DR) remains the leading cause of vision loss and blindness in people of working age, in spite of the fact that current treatments are effective. Vision loss occurs in DR due ...

Valo Health’s Rho kinase (ROCK) 1 and 2 inhibitor has failed to reduce the severity of diabetic retinopathy in a phase 2 trial, leading the Flagship-founded biotech to drop the candidate.

Diabetic retinopathy is a common complication in people with type 1 and type 2 diabetes, progressing from mild, moderate, and ...

Early detection and monitoring are key to the diagnosis and management of ocular diseases, including glaucoma, retinal and ...

The Diabetic Retinopathy Clinical Research (DRCR) Network, which includes over 199 participating sites, is currently evaluating many of these treatments in RCTs.